ONCT - Oncternal Therapeutics

-

$undefined

N/A

(N/A)

Oncternal Therapeutics NasdaqCM:ONCT Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Location: 12230 El Camino Real, San Diego, CA, 92130, United States | Website: https://www.oncternal.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Short % of Float

0.53%

Insider Ownership

9.23%

Institutional Own.

12.07%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ONCT-808 (CAR-T) Details
Hematologic malignancies, Cancer, B-cell lymphoma

Phase 1/2

Data readout

ONCT-534 Details
Cancer, Castration-resistant prostate cancer

Failed

Discontinued

Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details
Blood cancer, Cancer, Mantle cell lymphoma

Failed

Discontinued

ONCT-216 (TK216) (EWS-FLI1 inhibitor) Details
Relapsed/refractory Ewing sarcoma, Cancer

Failed

Discontinued

Failed

Discontinued

Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details
Blood cancer, Chronic lymphocytic leukemia, Cancer, Mantle cell lymphoma

Failed

Discontinued